Grifols stock extended its slide, plunging more than 20 percent over two trading days after Brookfield Asset Management, the Canadian investment firm, walked away from pursuing a public takeover of the plasma-derived products group. The company is actively seeking to refinance 1.4 billion euros of debt that matures in 2025, a move aimed at stabilizing liquidity and preserving financial flexibility in a difficult funding environment. The renewed weakness placed Grifols at the front of losses on both the Ibex 35 and the Continuous Market, with Class A shares sliding about 11.75 percent to 8.55 euros and Class B shares down about 13.68 percent to 6.465 euros, during the session.
Industry observers note that refinancing the near-term debt would help smooth the company’s maturity profile and reinforce its ability to fund ongoing operations. The plan appears to involve strengthening cash generation, assessing the balance between cash flow use and new borrowings, and maintaining prudent liquidity for a business with substantial leverage. Analysts stress that these steps are part of a broader effort to reassure investors and lenders while the company reassesses its strategic options in a volatile market.
CEO Ignacio Abía outlined the immediate objective as refinancing the 370 million euros in bonds due in 2025. He indicated the firm could service the debt with its cash flow but cautioned against being overly rigid in financing choices. Beyond the near-term bond, Grifols is also negotiating the extension of a renewable credit line of up to 1,000 million USD, maturing in November 2025, a detail reported by the same outlet. This combination of refinancing and liquidity tools is intended to provide a clearer runway for the company to execute its long-term plan amid ongoing market volatility.
Grifols confirmed that its Capital Markets Day will be held in the first quarter of 2025, after postponing this event that was originally scheduled for October 10 to early September. The company says the event will serve to illuminate its strategy, highlight ongoing investments, and outline milestones meant to drive sustained shareholder value. Investors will be looking for clarity on growth initiatives, product launches, and cost-optimization programs that could strengthen margins over time.
The top governance body of the Catalan group met in the afternoon for an extraordinary session to review Brookfield Asset Management’s unit, Brookfield Capital Partners, decision not to launch a public acquisition offer. Grifols stated that its board and management remain fully committed to executing the strategic plan designed to increase long-term value. The firm added that at its next meeting with shareholders and investors it will present its strategic vision and initiatives intended to unlock opportunities for growth and maintain a steady performance. The leadership emphasized discipline in pursuing value creation while staying adaptable to changing market conditions.
Deuda superior a 9.000 millones
Grifols reported a net debt of 9.208 billion euros as of September 30, with 8.128 billion euros in net financial debt and 1.080 billion euros associated with lease obligations for plasma centers. The company reduced its net financial debt from 9.396 billion at the end of the second quarter to 9.208 billion at the close of the third quarter, according to the balance sheet presented by the group. This positioning reflects a concerted effort to manage leverage while continuing to fund manufacturing, research, and patient-focused initiatives across its global footprint. The figures underscore the ongoing challenge of balancing growth investments with the need to maintain a stable capital structure in a sector that demands heavy capital expenditure and rigorous risk management.